巨子 ICON - 財經股票資訊及專家分析
搜尋 股票

Aptose Biosciences

APTO
最少15分鐘延遲,股票資訊由第三方資訊供應商提供
・Aptose Biosciences - 延遲價格・最後更新於 24/01 22:00
最高位
--
最低位
--
開市價
--
前收市價
1.200
成交量(千)
--
成交額(百萬)
--
買入
--
賣出
--
每手股數
--
市值(百萬)
106.74
市盈率
--
息率
--
差價
--
52週高低
7.200 - 1.080
所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱
Aptose Biosciences
證券代碼
APTO.US
所屬板塊
Biotechnology
公司業務
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. CG026806 (CG-806), its panFMS-like tyrosine kinase 3 / pan-Bruton's tyrosine kinase inhibitor, is enrolling patients in a Phase 1, multicenter, open label, dose-escalation study with expansions to assess the safety, tolerability, PK, and preliminary efficacy of CG-806 in patients with chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL).
發行量
88943243
公司總部
251 Consumers Road, Suite 1105
公司網址
https://www.aptose.com
公司電郵
ir@aptose.com
公司電話
+1 650 718-5028
暫無內容

關於

Aptose Biosciences(APTO.US)所屬的行業板塊為Biotechnology。
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. CG026806 (CG-806), its panFMS-like tyrosine kinase 3 / pan-Bruton's tyrosine kinase inhibitor, is enrolling patients in a Phase 1, multicenter, open label, dose-escalation study with expansions to assess the safety, tolerability, PK, and preliminary efficacy of CG-806 in patients with chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL).
詳細公司背景可參考: https://www.aptose.com